机译:发现口服白三烯C4合成酶抑制剂(1S,2S)-2 - ({5- [(5-氯-2,4-二氟苯基)(2-氟-2-甲基丙基)氨基] -3-甲氧基吡嗪-2- Y1}羰基)环丙烷羧酸(AZD9898)作为哮喘的新治疗方法
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
Orexo AB Virdings Alle 32A SE-75450 Uppsala Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Chem Dev Pharmaceut Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Discovery Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Discovery Sci SE-43183 Molndal Sweden;
Orexo AB Virdings Alle 32A SE-75450 Uppsala Sweden;
AstraZeneca Biopharmaceut Clin Pharmacol &
Safety Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Discovery Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Discovery Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Discovery Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Prod Dev Pharmaceut Sci SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
AstraZeneca Biopharmaceut Early Resp Inflammat &
Autoimmun SE-43183 Molndal Sweden;
机译:发现口服白三烯C4合成酶抑制剂(1S,2S)-2 - ({5- [(5-氯-2,4-二氟苯基)(2-氟-2-甲基丙基)氨基] -3-甲氧基吡嗪-2- Y1}羰基)环丙烷羧酸(AZD9898)作为哮喘的新治疗方法
机译:N-(4-氟-3-甲氧基苄基)-6-(2-((((2S,5R)-5-(羟甲基)-1,4-二恶烷-2-基)甲基)-2H-四唑-的发现5-基)-2-甲基嘧啶-4-羧酰胺。高选择性和口服生物利用基质金属蛋白酶-13抑制剂对骨关节炎的潜在治疗。
机译:发现4-[(2S)-2-{[4-(4-氯苯氧基)苯氧基]甲基} -1-吡咯烷基]丁酸(DG-051)作为白三烯B4生物合成的新型白三烯A4水解酶抑制剂
机译:具有5-(5-亚甲基-4-氧代-45-二氢噻唑-2-基氨基)间苯二甲酸骨架的白三烯C4合酶抑制剂
机译:探测口服白三烯C4合酶抑制剂(1S,2S)2 - ({5- (5-氯-2,4-二氟苯基)(2-氟-2-甲基丙基)氨基 -3-甲氧基吡嗪-2-基}羰基)环丙烷羧酸(AZD9898)作为哮喘的新治疗方法